ERBB2 and triple-negative breast carcinoma: Ganetespib showed stronger anti-tumor activity compared to tanespimycin over a broader range of breast cancer subtypes, including HER2-normal cancer and triple-negative breast cancer (TNBC), with a more favorable safety and toxicity profile [219].